Harvard Bioscience, Inc. logo

Harvard Bioscience, Inc.

HBIO

NASDAQHealthcareMedical - Instruments & Supplies

Latest quote

$7.47

−$0.07 · -0.93%

Aug 21, 3:55 PM ET

HBIO company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

46

Fair Value

Momentum

44

Neutral

Sentiment

51

Mixed

Risk resilience

33

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
John D. Duke
Listed since
Dec 7, 2000
Employees
328

Market position

Volume
10.66K
0.41× average
Average volume
25.93K
Average daily volume
Market cap
33.74M USD
Beta
1.49
Market reference 1

Financials

Financial snapshot

Latest / TTM

Financial health

Altman Z-score
-2.58
Piotroski F-score
5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends71%22%-28%-78%Gross margin, FY2021: 56.90%Gross margin, FY2022: 53.66%Gross margin, FY2023: 58.86%Gross margin, FY2024: 58.18%Gross margin, FY2025: 53.01%Operating margin, FY2021: 1.74%Operating margin, FY2022: -6.12%Operating margin, FY2023: 1.69%Operating margin, FY2024: -6.60%Operating margin, FY2025: -0.73%Net margin, FY2021: -0.24%Net margin, FY2022: -8.40%Net margin, FY2023: -3.04%Net margin, FY2024: -13.18%Net margin, FY2025: -65.51%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 56.90%. Gross margin FY2022 53.66%. Gross margin FY2023 58.86%. Gross margin FY2024 58.18%. Gross margin FY2025 53.01%. Operating margin FY2021 1.74%. Operating margin FY2022 -6.12%. Operating margin FY2023 1.69%. Operating margin FY2024 -6.60%. Operating margin FY2025 -0.73%. Net margin FY2021 -0.24%. Net margin FY2022 -8.40%. Net margin FY2023 -3.04%. Net margin FY2024 -13.18%. Net margin FY2025 -65.51%.

Income trends

Revenue

86.55M USD-8.06%

Operating income

−629K USD+89.87%

Net income

−56.7M USD-357.07%
Income trends across reported periods136.46M USD66.22M USD−4.02M USD−74.26M USDRevenue, FY2021: 118.9M USDRevenue, FY2022: 113.34M USDRevenue, FY2023: 112.25M USDRevenue, FY2024: 94.14M USDRevenue, FY2025: 86.55M USDOperating income, FY2021: 2.07M USDOperating income, FY2022: −6.93M USDOperating income, FY2023: 1.89M USDOperating income, FY2024: −6.21M USDOperating income, FY2025: −629K USDNet income, FY2021: −288K USDNet income, FY2022: −9.52M USDNet income, FY2023: −3.42M USDNet income, FY2024: −12.41M USDNet income, FY2025: −56.7M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 118.9M USD. Revenue FY2022 113.34M USD. Revenue FY2023 112.25M USD. Revenue FY2024 94.14M USD. Revenue FY2025 86.55M USD. Operating income FY2021 2.07M USD. Operating income FY2022 −6.93M USD. Operating income FY2023 1.89M USD. Operating income FY2024 −6.21M USD. Operating income FY2025 −629K USD. Net income FY2021 −288K USD. Net income FY2022 −9.52M USD. Net income FY2023 −3.42M USD. Net income FY2024 −12.41M USD. Net income FY2025 −56.7M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue86.55M USD94.14M USD112.25M USD113.34M USD118.9M USD
Cost of goods sold40.67M USD39.37M USD46.18M USD52.52M USD51.25M USD
Gross profit45.88M USD54.77M USD66.07M USD60.82M USD67.65M USD
Research and development8.83M USD10.41M USD11.76M USD12.33M USD10.8M USD
Selling, general, and administrative36.96M USD43.71M USD46.89M USD49.53M USD48.95M USD
Operating expenses46.51M USD60.98M USD64.18M USD67.75M USD65.59M USD
Interest expense4.92M USD3.21M USD3.59M USD2.55M USD1.54M USD
Depreciation and amortization5.95M USD6.98M USD7M USD7.58M USD7.62M USD
Operating income−629K USD−6.21M USD1.89M USD−6.93M USD2.07M USD
Net income−56.7M USD−12.41M USD−3.42M USD−9.52M USD−288K USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 5 misses, 1 met estimate
Average EPS surprise
-282.19%
11 comparable reports
Latest EPS result
-0.14
Estimate -0.21 · Beat by 33.33%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.70.22-0.26-0.74Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 12, 2025: actual 0.6, estimate 0.07, surprise +757.14%, Beat. Q2 2025, reported May 12, 2025: actual -0.1, estimate -0.2, surprise +50.00%, Beat. Q3 2025, reported Aug 11, 2025: actual -0.1, estimate -0.25, surprise +60.00%, Beat. Q4 2025, reported Nov 6, 2025: actual -0.276, estimate 0.05, surprise -652.00%, Miss. Q1 2026, reported Mar 12, 2026: actual -0.64, estimate 0.04, surprise -1700.00%, Miss. Q2 2026, reported May 12, 2026: actual -0.33, estimate -0.62, surprise +46.77%, Beat. Q3 2026, reported Aug 11, 2026: actual -0.14, estimate -0.21, surprise +33.33%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.17, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates25.54M22.95M20.36M17.77MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 12, 2025: actual 24.56M USD, estimate 24.15M USD, surprise +1.68%, Beat. Q2 2025, reported May 12, 2025: actual 21.77M USD, estimate 19.2M USD, surprise +13.41%, Beat. Q3 2025, reported Aug 11, 2025: actual 20.45M USD, estimate 18.75M USD, surprise +9.07%, Beat. Q4 2025, reported Nov 6, 2025: actual 20.59M USD, estimate 20M USD, surprise +2.96%, Beat. Q1 2026, reported Mar 12, 2026: actual 23.74M USD, estimate 23.1M USD, surprise +2.75%, Beat. Q2 2026, reported May 12, 2026: actual 20.76M USD, estimate 21.2M USD, surprise -2.10%, Miss. Q3 2026, reported Aug 11, 2026: actual 22.73M USD, estimate 21.45M USD, surprise +5.95%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 21.8M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

5 ratings
Strong buy00%
Buy480%
Hold120%
Sell00%
Strong sell00%

Recent analyst actions

2 institutions

HBIO news

HBIO peers

ETFs holding HBIO

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research HBIO

research.disclaimer